Figures & data
Figure 1. Ex vivo fluorescence of Doxorubicin in organs collected from mice treated with free doxorubicin (DOX) or with nanocapsules containing selol and doxorubicin (NCS-DOX) at 2, 4 and 8 h post-administration. Each panel above shows the organs of one representative animal out of three studied for each time and treatment.
![Figure 1. Ex vivo fluorescence of Doxorubicin in organs collected from mice treated with free doxorubicin (DOX) or with nanocapsules containing selol and doxorubicin (NCS-DOX) at 2, 4 and 8 h post-administration. Each panel above shows the organs of one representative animal out of three studied for each time and treatment.](/cms/asset/3b9927c5-793a-4bbe-a7c1-667fa9e0018d/ianb_a_1478423_f0001_c.jpg)
Figure 2. Graphs presents the quantitative evaluation the DOX-specific fluorescence photon counts of DOX (free doxorubicin) and nanocapsules containing selol and doxorubicin (NCS-DOX), as photons per second per gram of tissue (p/s/g). Data are expressed as mean ± standard error of the mean for three animals.
![Figure 2. Graphs presents the quantitative evaluation the DOX-specific fluorescence photon counts of DOX (free doxorubicin) and nanocapsules containing selol and doxorubicin (NCS-DOX), as photons per second per gram of tissue (p/s/g). Data are expressed as mean ± standard error of the mean for three animals.](/cms/asset/4c600121-de01-4d7d-be02-6b334d12d463/ianb_a_1478423_f0002_c.jpg)
Figure 3. Graphs represents the area under the curve of the data plotted in . Data are expressed as mean ± standard error of the mean for three animals.
![Figure 3. Graphs represents the area under the curve of the data plotted in Figure 2. Data are expressed as mean ± standard error of the mean for three animals.](/cms/asset/fef9d734-f24a-4478-886d-5a5eb00f6699/ianb_a_1478423_f0003_b.jpg)
Figure 4. Graphs represents evolution of 4T1 tumours volume in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS) and control group (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Treatments were performed at days 0, 3, 6 and 9 (arrows). Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a=p < .05 versus all other treatments.
![Figure 4. Graphs represents evolution of 4T1 tumours volume in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS) and control group (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Treatments were performed at days 0, 3, 6 and 9 (arrows). Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a=p < .05 versus all other treatments.](/cms/asset/8a263e0c-b2d4-4145-909c-2d994115ff34/ianb_a_1478423_f0004_c.jpg)
Figure 5. Graphs represent weight alteration in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), control group with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v).during the experiments. Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a = p < .05 versus all other treatments.
![Figure 5. Graphs represent weight alteration in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), control group with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v).during the experiments. Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a = p < .05 versus all other treatments.](/cms/asset/cdaf2c5b-618d-4bd8-b6ce-6f4e3dcf760c/ianb_a_1478423_f0005_c.jpg)
Figure 6. Graphs represent creatine kinase MB (CK-MB) activity in the serum of mice treated with doxorubicin alone (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), and control mice, with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Data are expressed as mean ± standard error of the mean. a = p < .05 when compared to the other groups, except NCS.
![Figure 6. Graphs represent creatine kinase MB (CK-MB) activity in the serum of mice treated with doxorubicin alone (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), and control mice, with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Data are expressed as mean ± standard error of the mean. a = p < .05 when compared to the other groups, except NCS.](/cms/asset/2d2f52b0-b30e-4906-8a4b-059a46aa2da2/ianb_a_1478423_f0006_b.jpg)
Figure 7. Optical microscopy images of heart tissue of: (A) control tumour-bearing mice (received vehicle only, which consisted of an aqueous solution of glucose 5% w:v), (B) mice treated with nanocapsules of selol (NCS), (C) mice treated with doxorubicin alone (DOX), and (D) mice treated with nanocapsules containing selol and doxorubicin (NCS-DOX). Arrows in A indicate parallel muscle fibers and the perpendicular intercalated discs. The arrow in C indicates wavy muscle fibers. The circle in D shows inflammatory infiltrate. Classical staining with hematoxylin and eosin was used.
![Figure 7. Optical microscopy images of heart tissue of: (A) control tumour-bearing mice (received vehicle only, which consisted of an aqueous solution of glucose 5% w:v), (B) mice treated with nanocapsules of selol (NCS), (C) mice treated with doxorubicin alone (DOX), and (D) mice treated with nanocapsules containing selol and doxorubicin (NCS-DOX). Arrows in A indicate parallel muscle fibers and the perpendicular intercalated discs. The arrow in C indicates wavy muscle fibers. The circle in D shows inflammatory infiltrate. Classical staining with hematoxylin and eosin was used.](/cms/asset/ef44722d-8afa-4358-8e1b-961b2bca4079/ianb_a_1478423_f0007_c.jpg)